Modern Chinese Medicine Group Co., Ltd.'s (HKG:1643) Shares Bounce 33% But Its Business Still Trails The Market
Modern Chinese Medicine Group Co., Ltd. (HKG:1643) shareholders would be excited to see that the share price has had a great month, posting a 33% gain and recovering from prior weakness. Unfortunat
Earnings Troubles May Signal Larger Issues for Modern Chinese Medicine Group (HKG:1643) Shareholders
A lackluster earnings announcement from Modern Chinese Medicine Group Co., Ltd. (HKG:1643) last week didn't sink the stock price. We think that investors are worried about some weaknesses underlying
現代中藥集團:2023年報
Have Insiders Sold Modern Chinese Medicine Group Shares Recently?
We wouldn't blame Modern Chinese Medicine Group Co., Ltd. (HKG:1643) shareholders if they were a little worried about the fact that Xinlei Sun, the Executive Chairman recently netted about HK$18m sell
Modern Chinese Medicine Group (01643.HK) profit before tax fell 45.1% to 68.3 million yuan in 2023
Gelonghui March 22 | Modern Chinese Medicine Group (01643.HK) announced that for the year ended December 31, 2023, the Group recorded revenue of approximately RMB 344.1 million in 2023, a decrease of approximately RMB 55.6 million or 13.9% compared with the fiscal year ending 2022. The decline in revenue was mainly due to changes in government policies, which led to a decrease in orders from dealers. Profit before tax decreased by about 45.1% from about RMB 124.3 million in 2022 to about RMB 68.3 million as of 2023, mainly due to changes in government policies, the decrease in dealer orders
MODERN CHI MED: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Modern Chinese Medicine Group (01643.HK) plans to hold a board meeting on March 22 to consider and approve the annual results
Gelonghui, March 13, 丨 Modern Chinese Medicine Group (01643.HK) announced that the company will hold a board meeting on March 22, 2024 (Friday). The agenda includes considering and approving the annual results of the company and its subsidiaries for the year ended 31 December 2023 and considering payment of a final dividend proposal (if any).
MODERN CHI MED: DATE OF BOARD MEETING
Modern Chinese Medicine Warns of Up to 48% Profit Slump
Modern Chinese Medicine Group (HKG:1643) expects a net profit of between 46 million yuan and 51 million yuan for the year 2023, down 42% to 48% from 87.8 million yuan in 2022, according to a filing wi
Hyundai Traditional Chinese Medicine Group (01643) issued a profit warning. The estimated annual net profit of 46 million yuan to 51 million yuan decreased by about 42% to 48% year-on-year
Hyundai Chinese Medicine Group (01643) issued an announcement. It is expected that the Group will take...
Modern Chinese Medicine Group (01643) fell 10.80% and now reports 0.290 yuan, a 52-week low
As of 16:08, Modern Chinese Medicine Group (01643) is down 10.80% from yesterday's closing price and now reports a 52-week low of $0.290; the trading volume is 156,000 shares, with a turnover of HK$46,900.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Everbright Securities: Four Advantages of Accelerating Transformation and Upgrading of the Traditional Chinese Medicine Industry, Value Revaluation
The Zhitong Finance app learned that Everbright Securities published a research report saying that traditional Chinese medicine has rich clinical positioning and broad market space. Under medical reform policies and industry standards, quality, safety, and efficacy have continued to improve.
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
No Data